Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Risk Versus Benefit

Gretchen Henkel  |  Issue: April 2009  |  April 1, 2009

Although Dr. Reyna lauded the current era of patients becoming active decision makers, she cautioned that physicians must not abrogate their responsibility in helping patients make informed choices. “Healthcare providers have to think very carefully about ‘the bottom line’ of the information they communicate to patients. They are in a very important role of conveying that information,” she concluded.

Gretchen Henkel covered the 2008 ACR/ARHP Annual Scientific Meeting for The Rheumatologist.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Reyna VF, Hamilton AJ. The importance of memory in informed consent for surgical risk. Med Decis Making. 2001;21:152-155.
  2. Lloyd A, Hayes P, Bell PRF, Naylor AR. The role of risk and benefit perception in informed consent for surgery. Med Decis Making. 2001;21:141-149.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Uncategorized Tagged with:BiologicsDisease-modifying antirheumatic drugs (DMARDs)FDASafety

Related Articles

    What Do Your Patients Think About You?

    May 9, 2012

    Why your practice needs patient-satisfaction surveys

    Drug Updates

    January 1, 2009

    Information on safety, labeling changes, and pharmaceutical research

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    FDA Provides 2020 Rheumatology Drug Update

    December 17, 2020

    Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences